Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.

著者	TAGA Takashi, Tanaka Shiro, HASEGAWA Daisuke, TERUI Kiminori, TOKI Tsutomu, IWAMOTO Shotaro, HIRAMATSU Hidefumi, MIYAMURA Takako, HASHII Yoshiko, MORITAKE Hiroshi, NAKAYAMA Hideki, TAKAHASHI Hiroyuki, SHIMADA Akira, TAKI Tomohiko, ITO Etsuro, HAMA Asahito, ITO Masafumi, KOH Katsuyoshi, HASEGAWA Daiichiro, SAITO Akiko M., ADACHI Souichi, TOMIZAWA Daisuke
journal or publication title	Leukemia
year	2021-09-01
URL	http://hdl.handle.net/10422/00013077

doi: 10.1038/s41375-021-01397-w(https://doi.org/10.1038/s41375-021-01397-w)

AUTHOR CORRECTION

Correction to: Post-induction MRD by FCM and *GATA1*-PCR are significant prognostic factors for myeloid leukemia of Down syndrome

Takashi Taga, Shiro Tanaka, Daisuke Hasegawa, Kiminori Terui, Tsutomu Toki, Shotaro Iwamoto, Hidefumi Hiramatsu, Takako Miyamura, Yoshiko Hashii, Hiroshi Moritake, Hideki Nakayama, Hiroyuki Takahashi, Akira Shimada, Tomohiko Taki, Etsuro Ito, Asahito Hama, Masafumi Ito, Katsuyoshi Koh, Daiichiro Hasegawa, Akiko M. Saito, Souichi Adachi and Daisuke Tomizawa

Correction to: *Leukemia* https://doi.org/10.1038/s41375-021-01157-w, published online 15 February 2021

Following the publication of this article, the authors noted an error in the data reported.

One patient in the AML-D11 study (showing negativity for both FCM-MRD and GATA1-MRD) was incorrectly reported dead after relapse following a data input error. After re-confirming the survival data for all other patients, the dataset has been updated and results are as follows.

- The number of patients who relapsed was decreased from 7 to 6.
- The 3-year event-free survival (EFS) and overall survival (OS) rates in the entire population ($n = 78$) were 88.5 and 91.0%.
- The 3-year EFS and OS rates in the SR patients ($n = 76$) were 90.8 and 93.4%.
- The 3-year EFS and OS rates were 95.0 and 96.7% in the FCM-MRD-negative population, and 60.0 and 80.0% in the positive population.
- Three-year EFS and OS rates were both 98.1% in the GATA1-MRD-negative population, and 57.1 and 71.4% in the positive population.
- The adjusted hazard ratios for the association of FCM-MRD with EFS and OS were 14.67 (95% CI, 2.00–107.79; $p = 0.01$) and 13.48 (0.81–224.27; $p = 0.07$), respectively, while multivariate analysis of GATA1-MRD did not converge in the updated dataset due to the limited number of events in the GATA1-MRD-negative population.

Table 2, Supplementary Table 4, and Figs. 3 and 4 have been corrected and are shown below.

The conclusions of the article remain unchanged.

Table 2. Multivariate Cox regression of FCM-MRD for event-free and overall survivals in the standard risk population.

	EFS			OS		
	HR	95% CI	*p*	HR	95% CI	*p*
Analysis of FCM-MRD ($N = 65$, including five MRD-positive patients)						
MRD at Time point 2						
Negative	Ref			Ref		
Positive	14.67	2.00–107.79	0.01	13.48	0.81–224.27	0.07
Cytogenetics						
Other abnormalities	Ref			Ref		
1q loss	6.03	0.53–69.21	0.15	10.68	0.67–170.88	0.09
Platelet (per 10^{10}/L increase)	1.09	0.87–1.37	0.45	0.95	0.65–1.37	0.77

MRD minimal residual disease, *EFS* event-free survival, *OS* overall survival, *HR* hazard ratio, *CI* confidence interval.
Multivariate analysis of GATA1-MRD did not converge due to the limited number of events in the GATA1-MRD-negative population.

Published online: 01 September 2021

Table S4. Univariate Cox regression of prognostic factors for event-free and overall survivals among 78 patients.

	EFS			OS		
	HR	**95% CI**	***p***	**HR**	**95% CI**	***P***
Age at diagnosis ≥ 24 months	4.71	1.05–21.07	0.04	5.28	0.88–31.61	0.07
Girl	0.81	0.18–3.64	0.79	1.71	0.29–10.22	0.56
Mosaic 21 trisomy	3.56	0.65–19.42	0.14	7.32	1.03–52.05	0.05
History of TAM	0.52	0.12–2.31	0.39	0.45	0.08–2.72	0.39
Cardiac complication	0.71	0.13–3.90	0.70	0.36	0.05–2.55	0.31
FAB classification						
M1	18.24	2.04–163.20	0.01	Not estimable		
M7	1.68	0.38–7.49	0.50	3.51	0.59–20.99	0.17
RAEB-T	1.28	0.25–6.57	0.77	2.10	0.35–12.60	0.41
RAEB	0.23	0.03–1.95	0.18	Not estimable		
RA	Not estimable			Not estimable		
White blood cells (per 10^6/L increase)	1.00	1.00–1.00	0.38	1.00	1.00–1.00	0.55
Hemoglobin (per 1-g/dL increase)	0.81	0.61–1.08	0.16	0.86	0.61–1.21	0.39
Platelet (per 10^{10}/L increase)	1.08	0.92–1.27	0.36	1.04	0.85–1.28	0.68
Cytogenetics						
Normal karyotype	0.54	0.06–4.60	0.57	Not estimable		
Monosomy 7	Not estimable			Not estimable		
Monosomy 7 (complex)	1.92	0.22–16.47	0.55	3.59	0.37–34.55	0.27
Sole trisomy 8	Not estimable			Not estimable		
Complex	1.78	0.21–15.23	0.60	2.83	0.29–27.23	0.37
1q loss	6.11	1.12–33.39	0.04	12.41	1.75–88.28	0.01
7p loss	1.35	0.16–11.60	0.78	2.18	0.23–20.97	0.50
Acquired +21	Not estimable			Not estimable		
Others	1.44	0.29–7.15	0.65	1.41	0.20–10.01	0.73
GATA1 mutation	7.03	0.84–58.88	0.07	Not estimable		

EFS event-free survival, OS overall survival, HR hazard ratio, CI confidence interval.

(a)



No. at Risk

Standard risk	76	75	74	71	70	70	65	55	43

(b)



No. at Risk

Standard risk	76	76	76	75	72	72	67	55	43

(a)



No. at Risk

Negative	60	60	60	58	58	58	54	47	36
Positive	5	5	4	4	3	3	3	1	1

(b)



No. at Risk

Negative	60	60	60	60	59	59	55	47	36
Positive	5	5	5	5	4	4	4	1	1

(c)



No. at Risk

Negative	52	52	52	52	52	52	47	38	30
Positive	7	6	5	5	4	4	4	4	4

(d)



No. at Risk

Negative	52	52	52	52	52	52	47	38	30
Positive	7	7	7	6	5	5	5	4	4